Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicitas Thol

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
Leukemia|October 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patientsMarius Bill, Jan-Niklas Eckardt, Konstanze Döhner, et al.
Blood|September 27, 2023
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapyDaria Frank, Pradeep Kumar Patnana, Jan Vorwerk, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
NEJM Evidence|February 6, 2024
Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElsa Bernard, Heinz Tuechler, Peter L Greenberg, et al.
Nature Medicine|August 5, 2020
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
Leukemia|October 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patientsMarius Bill, Jan-Niklas Eckardt, Konstanze Döhner, et al.
Blood|September 27, 2023
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapyDaria Frank, Pradeep Kumar Patnana, Jan Vorwerk, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
NEJM Evidence|February 6, 2024
Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElsa Bernard, Heinz Tuechler, Peter L Greenberg, et al.
Nature Medicine|August 5, 2020
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 13